Publications by authors named "David Swoboda"

Claim this Profile
T
Tumor Board-Inspired Multiagent Artificial Intelligence System for Interpreting Oncology Guidelines.
Jiasheng Wang, Kirti Arora, David M Swoboda, Aziz Nazha

JCO Clin Cancer Inform· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autonomous Analysis of Curated Patient Data Using a Large Language Model-Based Multiagent Framework.
Jiasheng Wang, David M Swoboda, Aziz Nazha

JCO Clin Cancer Inform· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia.
Somedeb Ball, Akriti G Jain, Najla Al Ali, Luis E Aguirre, Jan Philipp Bewersdorf, David M Swoboda

Am J Hematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progressive eosinophilia and mutation acquisition in AML treated with azacitidine and venetoclax.
Abigail Demers, Vincent Lok, Preston Perez, David M Swoboda

Leuk Lymphoma· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Myelodysplastic Syndrome in Pregnant Patients: Treatment Approaches and Considerations.
Erin McDonald, David M Swoboda

Semin Hematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comprehensive case study on successful multimodal therapy in philadelphia chromosome-positive acute myeloid leukemia with and mutations.
Syed Muhammad Waqar Haider, Mehwish Zehra, Nikesh N Shah, Eduardo M Sotomayor, David M Swoboda

Leuk Res Rep· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS).
Abhishek A Mangaonkar, David M Swoboda, Terra L Lasho, Christy Finke, Rhett P Ketterling

Leuk Res· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma.
Neeraj Y Saini, David M Swoboda, Uri Greenbaum, Junsheng Ma, Romil D Patel

Blood Cancer Discov· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?
Somedeb Ball, Akriti G Jain, Luis E Aguirre, Najla Al Ali, Yumeng Zhang, David M Swoboda

Am J Hematol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts.
David M Swoboda, Rashmi Kanagal-Shamanna, Andrew M Brunner, Thomas Cluzeau, Onyee Chan

Leukemia· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted.
Abhishek A Mangaonkar, David M Swoboda, Terra L Lasho, Christy Finke, Rhett P Ketterling

Leukemia· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy.
Anthony M Hunter, Najla Al Ali, Anne Mai, Savan Shah, David M Swoboda

Leuk Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma.
Geoffrey T Gibney, Jacob Zaemes, Shelly Shand, Neil J Shah, David Swoboda

J Immunother Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes.
Rami Komrokji, Virginia Volpe, Onyee Chan, Najla Al Ali, David Swoboda

Blood· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies.
Quinto J Gesiotto, David M Swoboda, Rory M Shallis, Najla Al Ali, Eric Padron

Clin Lymphoma Myeloma Leuk· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies.
Rory M Shallis, Jan Philipp Bewersdorf, David M Swoboda, Wei Wei, Lohith Gowda

Clin Lymphoma Myeloma Leuk· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic characteristics and prognostic significance of co-mutated ASXL1/SRSF2 acute myeloid leukemia.
Daniel R Richardson, David M Swoboda, Dominic T Moore, Steven M Johnson, Onyee Chan

Am J Hematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PTPN11 mutations are associated with poor outcomes across myeloid malignancies.
David M Swoboda, Najla Al Ali, Onyee Chan, Eric Padron, Andrew T Kuykendall

Leukemia· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The promise of macrophage directed checkpoint inhibitors in myeloid malignancies.
David M Swoboda, David A Sallman

Best Pract Res Clin Haematol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel therapies in myelodysplastic syndromes.
David M Swoboda, Quinto Gesiotto, David A Sallman

Curr Opin Hematol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moffitt Cancer Center study of 135 consecutive patients.
Abhishek A Mangaonkar, David M Swoboda, Giacomo Coltro, Terra L Lasho, Paul J Novotny

Leukemia· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutation-Driven Therapy in MDS.
David M Swoboda, David A Sallman

Curr Hematol Malig Rep· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T315I-mutated myeloid sarcoma.
Yumeng Zhang, David M Swoboda, Aditya Grover, Lisa Nodzon, Ling Zhang

Leuk Res Rep· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Descriptive analysis of genetic aberrations and cell of origin in Richter transformation.
Ami Chitalia, David M Swoboda, Justine N McCutcheon, Metin Ozdemirli, Nadia Khan

Leuk Lymphoma· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis